^
Association details:
Biomarker:BRCA2 underexpression
Cancer:Prostate Cancer
Drug Class:PARP inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Personalized Combination Therapies for Advanced Prostate Cancer with PARP Inhibitors

Published date:
05/28/2021
Excerpt:
We discovered that LNCaP cells expressed significantly lower levels of BRCA1/2 and ATM in comparison with VCaP and PC3, and PARPi treatment prompted a significant reduction in cell viability in LNCaP only.